148 related articles for article (PubMed ID: 16191370)
1. [Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw].
Meng XM; Yu SF; Wei MJ
Zhonghua Kou Qiang Yi Xue Za Zhi; 2005 Jul; 40(4):294-7. PubMed ID: 16191370
[TBL] [Abstract][Full Text] [Related]
2. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
3. OPG, RANK and RANK ligand expression in thyroid lesions.
Heymann MF; Riet A; Le Goff B; Battaglia S; Paineau J; Heymann D
Regul Pept; 2008 Jun; 148(1-3):46-53. PubMed ID: 18367263
[TBL] [Abstract][Full Text] [Related]
4. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts.
Liu B; Yu SF; Li TJ
J Oral Pathol Med; 2003 Jul; 32(6):367-75. PubMed ID: 12787044
[TBL] [Abstract][Full Text] [Related]
5. Expression of receptor activator of NF-κB ligand and osteoprotegerin in peripheral giant cell granulomas of the jaws.
Fanourakis G; Lazaris AC; Krithinakis S; Tosios KI; Sklavounou A; Tseleni-Balafouta S
J Oral Pathol Med; 2010 Oct; 39(9):687-9. PubMed ID: 20701665
[TBL] [Abstract][Full Text] [Related]
6. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
7. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
Tat SK; Padrines M; Theoleyre S; Couillaud-Battaglia S; Heymann D; Redini F; Fortun Y
Bone; 2006 Oct; 39(4):706-15. PubMed ID: 16750945
[TBL] [Abstract][Full Text] [Related]
8. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
9. Markers of bone remodeling in neoplastic and bone-related lesions.
Elias LS; Costa RF; Carvalho MA; Batista AC; Silva TA; Leles CR; Mendonça EF
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Nov; 110(5):624-31. PubMed ID: 20955951
[TBL] [Abstract][Full Text] [Related]
10. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
[TBL] [Abstract][Full Text] [Related]
11. Expression of bone resorption regulators (RANK, RANKL, and OPG) in odontogenic tumors.
Andrade FR; Sousa DP; Mendonça EF; Silva TA; Lara VS; Batista AC
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Oct; 106(4):548-55. PubMed ID: 18928898
[TBL] [Abstract][Full Text] [Related]
12. Comparative expression of RANK, RANKL, and OPG in keratocystic odontogenic tumors, ameloblastomas, and dentigerous cysts.
da Silva TA; Batista AC; Mendonça EF; Leles CR; Fukada S; Cunha FQ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Mar; 105(3):333-41. PubMed ID: 18061491
[TBL] [Abstract][Full Text] [Related]
13. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
[TBL] [Abstract][Full Text] [Related]
14. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
15. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
Wang J; Wang K; Shi Z; Zhang M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
[TBL] [Abstract][Full Text] [Related]
16. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
17. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
18. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
20. Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves.
Steinmetz M; Skowasch D; Wernert N; Welsch U; Preusse CJ; Welz A; Nickenig G; Bauriedel G
J Heart Valve Dis; 2008 Mar; 17(2):187-93. PubMed ID: 18512489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]